We investigated the potential of diacerein, a small molecule that interferes with the MMP‐9 regulatory pathway, to improve wound healing in a 5‐year old RDEB patient presenting with chronic, generalized skin involvement unresponsive to previous treatment approaches. Here, MMP9 is linked to recessive dystrophic epidermolysis bullosa.